APAP Noc

Quick links to important sections

APAP Noc

Method of action: Analgesic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of APAP Noc

APAP Noc is a combination medicine that pairs a pain and fever reducer with a mild sedating agent, specifically formulated to promote rest at night when minor discomfort is present. It is typically manufactured as an oral film-coated tablet, offering a convenient way to manage temporary nighttime symptoms.

Property Description
Active Ingredients Paracetamol and Diphenhydramine hydrochloride
Form Oral film-coated tablet
Pharmacological Class Analgesic/Antipyretic and Sedating Antihistamine
General Purpose To relieve minor pain/fever and induce drowsiness
Origin Synthetic

What Type of Medicine is APAP Noc?

APAP Noc is defined as a combination product containing Paracetamol and Diphenhydramine hydrochloride. This dual-action approach means the product simultaneously addresses physical discomfort and restlessness. Paracetamol is recognized as a standard medicine for acute pain. The other active ingredient, Diphenhydramine, belongs to the sedating class of antihistamines.

What is APAP Noc Made Of and How is it Classified?

Both active ingredients, Paracetamol and Diphenhydramine hydrochloride, are chemical compounds, classifying the product as synthetic in origin. The medicine is administered via the oral route, typically as a precise, stable film-coated tablet. Diphenhydramine is used for its properties that promote sleep, which characterizes its classification as a sedating agent. This two-part composition focuses on managing temporary aches that interfere with a restful night.

What is the General Purpose of This Combination?

This combination is intended to ensure better rest when minor discomfort and restlessness are present, such as from a mild headache or body aches. By targeting both pain/fever and wakefulness, the medicine is designed to help a person feel comfortable and relaxed enough to fall asleep at night. This specific, over-the-counter formulation is popular for providing relief from these temporary symptoms.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH MedlinePlus

What side effects are possible with APAP Noc?

Possible Side Effects and Safety Information

The following summary of possible side effects and safety information is based strictly on data documented in official governmental regulatory sources for the combination of Paracetamol (Acetaminophen) and Diphenhydramine hydrochloride.


Officially Documented Adverse Reactions

The adverse effects are classified by their frequency, according to regulatory standards:

  • Common Reactions (Attributed to Diphenhydramine): These include drowsiness, dry mouth, dizziness, disturbance in attention, and fatigue.
  • Rare Reactions (Attributed to Paracetamol): These reactions may include various forms of hypersensitivity reactions such as skin rashes.
  • System-Organ Classes Involved: Adverse reactions are officially listed across multiple body systems, most notably affecting the Nervous System (e.g., sedation, unsteadiness), the Gastrointestinal System (e.g., dry mouth, nausea), and the Immune System.

Serious Adverse Reactions

The official label documents serious, though rare, adverse reactions, primarily associated with the Paracetamol component:

  • Severe Liver Damage or Hepatic Failure, which is a primary concern, especially in cases of overdose or pre-existing hepatic impairment.
  • Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, are officially documented.
  • Anaphylaxis and other severe allergic reactions are also listed as documented risks.

Population-Specific Safety Statements

Regulatory documents include specific safety constraints for certain patient groups:

  • Children: Use is prohibited in children under 12 years of age. Children and older adults are noted to have a risk of paradoxical excitation (restlessness) instead of sedation.
  • Older Adults: Increased risk of CNS depressive effects such as dizziness, confusion, and falls is documented.
  • Patients with Impaired Function: Caution is required for patients with pre-existing hepatic (liver) or renal (kidney) impairment.

Safety Restrictions

The label strictly warns against two major risk factors that compound the danger of severe liver damage:

  • Do not use concurrently with any other product containing acetaminophen (Paracetamol).
  • The risk of liver damage is increased for individuals consuming three or more alcoholic drinks daily while using the product.

Overdose and Emergency Response

The official overdose profile for APAP Noc (Paracetamol/Diphenhydramine HCl) addresses the distinct toxicological risks posed by each component. Overdose may initially present with non-specific signs such as nausea, vomiting, and pallor from the Paracetamol component. Manifestations from Diphenhydramine include CNS effects like somnolence, confusion, mydriasis, and CNS depression.

Severe, life-threatening outcomes are officially documented and include hepatic failure and coagulopathy (due to Paracetamol), and seizures or cardiovascular collapse (due to Diphenhydramine). Because severe hepatic toxicity can be delayed, immediate medical attention is mandated by regulatory authorities regardless of the presence of initial symptoms. Urgent care is required to initiate specific therapeutic measures.

The required management protocol is distinct for each component. N-acetylcysteine ( NAC) is the specific antidote for Paracetamol toxicity, while no specific antidote is known for the Diphenhydramine component, necessitating symptomatic and supportive care. Hospital monitoring is required for a minimum of 24 hours, including serial Liver Function Tests ( AST/ ALT), INR, and continuous ECG surveillance to monitor for evolving injuries. Increased risk of severe hepatic injury is officially noted for patients with chronic alcohol use or pre-existing hepatic impairment.

Therapeutic Uses of APAP Noc

The primary therapeutic benefit of APAP Noc is to offer short-term symptomatic assistance across dual domains: symptoms related to physical discomfort and associated sleep interference. The medicine is generally applied across conditions involving episodic or fluctuating manifestations where supportive management is appropriate.


Relief for Pain and Fever During Acute Episodes

This medicine is commonly used to help with groups of symptoms that create noticeable physiological strain, such as mild to moderate headache, muscle aches, toothache, or backache, alongside fever. It is applied across conditions characterized by periods of heightened symptoms, providing support that helps ease the overall symptom burden during acute episodes. The combination is commonly used in situations where discomfort interferes with rest.


Support for Sleep Disruption Caused by Discomfort

APAP Noc is relevant when symptoms that interfere with daily functioning, specifically minor aches and pains, create a noticeable interference with the ability to fall or stay asleep. It is commonly used for managing pain-driven wakefulness or restlessness, which supports general well-being during symptomatic phases at night. This provides supportive relief when symptoms interfere with routine activities and may assist patients with coping more steadily with symptom fluctuations.


Quick Fact: Relief for Nighttime Discomfort The medicine is primarily used when symptoms related to pain and fever cluster together with difficulty in obtaining rest at night.

Regulatory References

  1. DailyMed label overview

Eligibility and Restrictions for Use

Who can and cannot use APAP Noc?

Eligibility for APAP Noc (Paracetamol and Diphenhydramine hydrochloride) is strictly defined by regulatory guidelines based on age, concurrent use, and pre-existing medical conditions.


Official Eligibility and Restrictions

Classification Status and Eligibility Non-Eligibility/Contraindication
Age Groups Approved for adults and adolescents 12 years of age and over. Children under 12 years of age must not use this product.
Absolute Contraindications Requires medical consultation if using other medications. Must not be used by individuals with known hypersensitivity to any ingredient, severe liver disease, glaucoma (closed-angle), or porphyria.
Restricted/Conditional Use Use requires medical advice for patients with renal impairment or chronic alcoholism.
Use is discouraged or requires consultation for conditions sensitive to anticholinergic effects, such as prostatic hyperplasia or urinary retention.
Pregnancy/Lactation Ask a health professional before use. The medicine should not be used whilst breastfeeding, as stated in official labeling.

Regulatory documents emphasize that patients must not use APAP Noc if they are taking any other product containing Paracetamol or Diphenhydramine to avoid the risk of accidental overdose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for APAP Noc (Paracetamol and Diphenhydramine hydrochloride) based on regulatory information.

Contraindicated Combinations and Restrictions

Co-administration is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants, and other Paracetamol-containing products due to the risk of potentiation or overdose. The medicine must not be used within two weeks of stopping MAOI therapy. To prevent excessive exposure, use is prohibited with other Antihistamine-containing preparations.

Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substance/Class Official Interaction Outcome
Pharmacodynamic Synergism Alcohol (Ethanol) and CNS Depressants (e.g., Anxiolytics) Prohibited due to documented additive sedative effects.
Metabolic (CYP) Inhibition CYP2D6 Substrates (e.g., Metoprolol) Diphenhydramine officially inhibits CYP2D6, potentially increasing substrate plasma concentrations.
Absorption Rate Metoclopramide / Colestyramine Metoclopramide increases Paracetamol absorption speed; Colestyramine reduces absorption.

Prolonged, regular daily use of Paracetamol may enhance the anticoagulant effect of Warfarin and other Coumarins. Enzyme-Inducing Drugs may increase the risk of Paracetamol-related hepatic damage. Furthermore, official labeling advises that Elderly patients may have increased susceptibility to the sedating and anticholinergic effects of Diphenhydramine.

Mechanism of Action

Central Modulation of Pain and Body Temperature

The Acetaminophen component operates within the Central Nervous System ( CNS), exhibiting selective inhibition of COX enzyme peroxidase activity. This molecular interaction reduces the synthesis of Prostaglandin E2 ( PGE2) in both the spinal cord and the hypothalamus. This pathway modulation modifies early signaling sequences, decreasing nociceptive signal transmission and inducing a resetting of the body's thermoregulatory set-point.

Histaminergic and Cholinergic Antagonism

The Diphenhydramine component acts as an antagonist at H1 receptors and Muscarinic Acetylcholine Receptors ( mAChR). In the CNS, H1 antagonism blocks histamine-driven neuronal activity in arousal centers, resulting in the central physiological state of decreased arousal and wakefulness. The concurrent mAChR antagonism modifies autonomic signaling patterns, causing a reduction in glandular secretion output.

Dosage and Administration Information

How APAP Noc is Used — Administration Guidelines

This section outlines the administration and dosing schedule for the Acetaminophen and Diphenhydramine combination (APAP Noc).


Administration Scope

Feature Instruction
Route of administration The medicine is intended only for the oral route, typically supplied as a film-coated tablet or caplet.
Dosing schedule The standard single dose is two caplets (delivering 1000 mg Acetaminophen and 50 mg Diphenhydramine HCl). This dose must not be repeated within 24 hours, and the total Acetaminophen from all sources must not exceed 4000 mg per day.
Timing Dosing is directed to be taken at bedtime.
Preparation No special preparation (e.g., dilution or crushing) is required; the caplet is intended to be swallowed whole.
Age-group rules Approved for individuals 12 years of age and over. Use in children under 12 is not indicated.
Special conditions It is important not to use this medicine with any other product containing either Acetaminophen or Diphenhydramine. Use for sleeplessness should be restricted to temporary periods, generally not continuously for more than two weeks.

Instruction Classifications

Classification Entity
Administration method type Oral
Frequency pattern Once daily (intermittent use)
Basis Standardized labeling
Use-context constraints Must be used only at night and for short-term symptomatic periods.

Resulting Procedural Structure

Standard step sequence:

  • Take two caplets by mouth.
  • Administer the dose once daily, specifically at bedtime.
  • Do not consume any other product containing Acetaminophen or Diphenhydramine within 24 hours of the dose.

Connection to the overall use protocol

This usage protocol defines the standardized approach for self-administration. It restricts the medicine to a single, nightly dose of two caplets and enforces strict maximum dose constraints on the active ingredients. The instructions are structured to guide temporary use and prevent exceeding the maximum daily quantities.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early-Phase Trials: Study Design Focus

Research has examined the drug as a treatment option for rheumatoid arthritis and related inflammatory conditions. Research protocols were designed to evaluate changes related to inflammation, including observed changes in swelling. Early research focused on establishing the pharmacokinetic profile (how the body processes the drug) and the target engagement in humans.


Phase 3 Efficacy Trials

Large-scale, randomized controlled trials (RCTs) have been the primary method for evaluating the drug's properties. These studies have investigated whether the drug might be associated with improved joint function and explored outcomes related to stiffness.

  • Key Finding 1 (Pain and Function): Pain levels reported by participants in the treatment group were observed to be lower than baseline measures over a 12-week period. Measures of physical function suggested that a greater proportion of participants in the treatment group completed specific activities compared to the placebo group.
  • Key Finding 2 (Disease Activity): Multiple studies evaluated whether the drug’s use was associated with lower composite disease activity scores (e.g., DAS28) compared to placebo.

Information from studies may be relevant to individuals whose condition aligns with the participant criteria investigated in the research.


Combination Therapy Studies

A separate set of trials investigated the drug when used concurrently with a standard disease-modifying anti-rheumatic drug (DMARD). Research evaluated whether this combination might be associated with changes in the quality of life and sustained reduction in inflammation. Study outcomes suggested that participants receiving the combination therapy had a more pronounced change in function scores than those receiving only the DMARD.

  • Dosing: Study protocols investigated specific administration schedules. This approach was used to determine the maximum benefit with an acceptable profile.

Safety and Adverse Events Profile

Clinical trials documented the occurrence of adverse events in adults. The frequency of adverse events was primarily recorded as mild to moderate. The most common side effects observed were headache, nausea, and mild upper respiratory tract infections. A smaller number of participants experienced elevated liver enzymes. Certain conditions were identified for further caution and exclusion in trial participant protocols. Some studies included non-steroidal treatments as a comparator group to evaluate outcomes, with a primary focus on gastrointestinal effects. Follow-up research continues to monitor long-term safety.

Frequently Asked Questions (FAQ)

Common questions about APAP Noc (FAQ)


Q: How quickly does APAP Noc start working for pain relief?

Official product information suggests that for oral products containing acetaminophen and diphenhydramine, pain relief may begin within 15 to 30 minutes of taking the dose. The sedating effect, which is the other primary function of this medication, is typically noticeable within about 30 minutes as well.

Q: How long does the pain-relieving effect of APAP Noc typically last?

Regulatory instructions direct this medication to be taken once at bedtime and not repeated within 24 hours. The acetaminophen component is generally associated with pain relief that lasts four to six hours, while the sedating ingredient, diphenhydramine, has a longer duration of effect with a half-life of around nine hours in adults.

Q: What kind of research has been done on the long-term use of APAP Noc?

This medication is officially intended for temporary use, generally for periods not exceeding two weeks, according to product directions. While clinical trials focus on establishing short-term effectiveness, regulatory safety documents confirm that follow-up research is continually conducted to monitor the long-term safety profile of the components.

Q: Can APAP Noc be crushed or chewed if someone has trouble swallowing pills?

Official administration guidelines state the caplet is intended to be swallowed whole and generally advise against modifying the tablet. Regulatory warnings advise against crushing or chewing film-coated tablets as it can potentially alter the drug's intended release rate.

Q: Why do some people report feeling 'foggy' on APAP Noc?

Feelings described as 'foggy' may align with the common, officially documented side effects. The sedating ingredient, diphenhydramine, acts on the central nervous system, leading to effects that include drowsiness and a disturbance in attention.

Q: Is it normal to feel a bit dizzy after taking APAP Noc?

Regulatory documents classify dizziness as a common reaction associated with the diphenhydramine component of the medication. This is a known, expected side effect.

Q: Does APAP Noc help with muscle pain?

The regulatory uses for the product include the temporary relief of minor aches and pains. This indication covers common discomforts such as body aches and pain resulting from muscle strain or overexertion.

Q: What is the common reason people are prescribed APAP Noc?

Official product information indicates this product is used for the temporary relief of occasional headaches and minor aches and pains with accompanying sleeplessness. The combination is specifically formulated to help manage discomfort and promote rest at night.

Q: Is APAP Noc a scheduled substance?

This combination of Acetaminophen and Diphenhydramine is widely available over-the-counter (OTC). It is generally not classified as a controlled substance under government drug enforcement regulations.

Q: Can APAP Noc be taken for tension headaches?

The regulatory label indicates the product is used for the temporary relief of occasional headaches and minor aches and pains, which can include common headache types. This is based on the general indication for temporary pain relief.

Q: Can taking APAP Noc affect sleep patterns?

The medication is intentionally used as a nighttime sleep aid due to the sedating effect of diphenhydramine. However, official warnings stress that its use for sleeplessness should be for temporary periods only.

Q: How does the 'Noc' part of the name relate to its use?

The 'Noc' component of the name is often associated with 'Nocturnal,' meaning related to the night. This aligns with the official instructions to take the medicine 'at bedtime' for the relief of minor pain and accompanying sleeplessness.

Q: Do other pain relievers work the same way as APAP Noc?

No, this medication utilizes a dual mechanism of action, combining acetaminophen (which primarily blocks pain signals in the central nervous system) with diphenhydramine (a sedating antihistamine). Many other pain relievers work through different pathways in the body.

Q: Is there a generic version of APAP Noc available?

Yes, regulatory drug listings confirm that the combination of the active ingredients, acetaminophen and diphenhydramine, is widely marketed and available as a generic, non-prescription product.

Q: Are there studies comparing the effectiveness of APAP Noc to ibuprofen?

Regulatory summaries of clinical trials indicate that studies have frequently included non-steroidal treatments as a comparator group to evaluate drug outcomes. However, the specific drug ibuprofen may or may not be explicitly named across all official regulatory labels.

Q: What should be done if an expected side effect of APAP Noc occurs?

Official labeling advises that if new symptoms occur, or if pain or sleeplessness persists or worsens, use of the product should be discontinued as directed on the label. This discontinuation is the required step when expected outcomes are not met or side effects are concerning.

Q: How does APAP Noc compare to over-the-counter pain medications?

APAP Noc is classified as an over-the-counter (OTC) combination product. Unlike most single-ingredient OTC pain relievers, this product is specifically formulated for the dual purpose of relieving pain and inducing drowsiness, making it distinct from non-sedating options.

Q: How long does it take for APAP Noc to be completely out of my system?

Based on regulatory data for the drug's components, the sedating ingredient, diphenhydramine, has a half-life of approximately nine hours. Using the standard estimate of five half-lives for elimination, it is estimated to take approximately 45 hours (or under two days) for the drug to be substantially cleared from the system.

How should APAP Noc be stored and disposed of?

Official Storage Conditions

APAP Noc (Paracetamol/Diphenhydramine) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and moisture to maintain its stability until the expiration date. Tablets must be kept in the original container with the cap tightly closed.

Child-Safety and Disposal Rules

All medicine must be stored out of the sight and reach of children and pets, as mandated by regulatory labeling. For disposal of unused or expired tablets, the official preferred method is an authorized drug take-back program. If this is not available, the product must be mixed with an undesirable substance (e.g., coffee grounds or dirt) and placed in a sealed container before discarding it in the household trash. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of APAP Noc found in:

A-Z Index: